Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

56%

5 of 9 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 3

4(44.4%)

Phase 1

3(33.3%)

Phase 2

2(22.2%)

9Total

Phase 3(4)

Phase 1(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02237950Phase 3Completed

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

Role: lead

NCT01577238Phase 3Completed

A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis

Role: lead

NCT01577537Phase 3Completed

A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis

Role: lead

NCT01201057Phase 2Completed

Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)

Role: lead

NCT00740584Phase 1Completed

Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

Role: lead

NCT02236156Phase 3Completed

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

Role: lead

NCT01437722Phase 2Completed

Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)

Role: lead

NCT00442910Phase 1Completed

Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women

Role: lead

NCT00370357Phase 1Completed

SPL7013 Gel - Male Tolerance Study

Role: lead

All 9 trials loaded